ANTIMICROBIAL CHEMOTHERAPY VIRTUAL CONFERENCE

1 & 2 February 2023

Jointly organised by the BSAC and GARDP

BRITISH SOCIETY FOR ANTIMICROBIAL CHEMOTHERAPY

GARDP
Global Antibiotic Research & Development Partnership

This virtual conference is jointly organised by BSAC and GARDP. For ACC2023, the collaborating organisations are Africa CDC and ReAct Africa.

AFRICA CDC
Centres for Disease Control and Prevention
Safeguarding Africa's Health

ReAct
AFRICA

PROGRAMME: 1 FEBRUARY

0930 POSTER VIEWING & EXHIBITION

1030 Introductory remarks
Professor Laura JV Piddock, Scientific Director, GARDP

SESSION ONE: KEYNOTE PRESENTATION
Chair: Professor Laura JV Piddock, Scientific Director, GARDP

1035
Is antimicrobial discovery responding to current needs? How do we move from here?
Dr Mirfin Mpundu, Director, ReAct Africa

1055
Q&A

1105
BREAK - POSTERS & EXHIBITION

SESSION TWO: DRUG DISCOVERY - NEW TARGETS AND NEW CHEMISTRY
Chair: Dr Keith Miller, Senior Lecturer in Medical Microbiology, Sheffield Hallam University

1115
Antiviral drug discovery: preparing for the next pandemic
Professor Rosemary Dorrington, Professor: Marine natural Products Research, Rhodes University

1130
Awakening sleeping antibiotics
Professor Gilles P. van Wezel, Director, Institute of Biology & Professor of Microbial Biotechnology, Leiden University, The Netherlands

1145
Bioinformatics as a tool to identify and synthesise of new antibiotics
Dr César de la Fuente, Presidential Assistant Professor, University of Pennsylvania

1200
Q&A

1210
BREAK - POSTERS & EXHIBITION

SESSION THREE: PRECLINICAL ANTIMICROBIAL DEVELOPMENT
Chair: Dr Christopher Longshaw, Senior Director, EU Scientific Affairs, Shionogi BV & BSAC Honorary Treasurer

1220
Recent developments in PK-PD
Professor Lena Friberg, Professor of Pharmacokinetics and Pharmacodynamics at the Department of Pharmacy, Uppsala University, Sweden

1235
Challenges of discovery of new antibiotics
Dr Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna

1250
Discovery and pre-clinical development of new antimicrobials in Africa
Dr Greg Basarab, H3D - University of Cape Town

1305
Q&A

1315
BREAK - POSTERS & EXHIBITION

SESSION FOUR: PANEL DISCUSSION - DEVELOPMENT OF NON-TRADITIONAL ANTIMICROBIALS
Chair: Dr Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna

1325
Panellists:
Dr Peter Jackson, Executive Director, INFEX Therapeutics Ltd, Dr Richard Alm, Chief Scientist, CARB-X, Dr Nagasuma Chandra, PhD Professor Department of Biochemistry Indian Institute of Science, Bangalore, India

1420
Q&A

1430
Day one closing remarks
Dr Christopher Longshaw, Senior Director, EU Scientific Affairs, Shionogi BV & BSAC Honorary Treasurer

1435 POSTER VIEWING & EXHIBITION

PROGRAMME: 2 FEBRUARY

0930 POSTER VIEWING & EXHIBITION

1030 Introductory remarks
Dr Christopher Longshaw, EU Scientific Advisor, Shionogi & BSAC Honorary Treasurer

SESSION FIVE: CLINICAL DEVELOPMENT AND USE OF NEW AGENTS
Chair: Alison Luckey, GARDP

1035
Zoliflodacin Phase 3 study
Professor Sinead Delany-Moretlwe, Director: Research, Wits RHI & Professor of Global Health & Infectious Diseases, University of the Witwatersrand, Johannesburg

1050
Clinical trials in countries with a high burden of drug resistance
Dr Ashima Bhatia MD – Chief Clinical Officer & Head, Global Clinical Development, Wockhardt & Dr Manish Shah, VP, Global Clinical Development, Wockhardt

1105
Compassionate use of Cefiderocol to treat documented XDR-AB infections at the intensive care unit
Professor Federico Pea, Full Professor of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Italy

1120
Q&A

1130
BREAK - POSTERS & EXHIBITION

SESSION SIX: ORAL POSTER PRESENTATIONS
Chair: Dr Mirfin Mpundu, Director, ReAct Africa

1140
Association of meropenem with ethambutol enhances the exposure of Mycobacterium tuberculosis peptidoglycan and promotes its synergistic killing
Mr Francisco Olivença, Research Institute for Medicines (iMed. ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal

1145
Assessment of availability of essential antimicrobial agents in north India
Dr Rachna Rohilla, Assistant Professor, Department of Pharmacology, AIIMS Bathinda

1150
The SA-UK Antimicrobial Drug Discovery Hub: Harnessing the potential of natural products as antimicrobial lead compounds
Miss Roxanne Leigh Higgitt, Department of Biochemistry and Microbiology, Rhodes University, Makhanda, South Africa

1155
Interplay Between Clinical Stringent Response-Activating Mutations, Antibiotic Tolerance and Bacterial Fitness
Dr Joanne Hobbs, Research Associate & Adjunct Assistant Professor, Department of Biochemistry & Microbiology, University of Victoria, Canada

1200
Infection control of Healthcare-associated infections in Ukraine
Dr Yulian Konechnyi, National Medical University, Lviv, Ukraine

1205
Q&A

1215
BREAK - POSTERS & EXHIBITION

PROGRAMME: 2 FEBRUARY CONTINUED

SESSION SEVEN: NATIONAL ACTION PLAN PROGRESS/POLICY
Chair: Dr Yewande Alimi, Antimicrobial Resistance (AMR) Program Coordinator, Africa Centres for Disease Control and Prevention & co-lead for the Africa Union Task force on AMR

1225
Development of the National Policy and Action Plan and accompanying strategies for Antimicrobial Resistance in Kenya
Dr Evelyn Wesangula, Senior AMR Control Specialist, East Central and Southern Africa Health Community (ECSA- HC)

1240
MAAP DATA
Dr Pascale Ondoa, Director of Science & New Initiatives, African Society for Laboratory Medicine (ASLM)

1255
Widening access to antibiotics in LMICs
Professor Samuel Kariuki, Chief Research Scientist and Director, Research and Development, Kenya Medical Research Institute (KEMRI), Kenya)

1310
Q&A

1320
BREAK - POSTERS & EXHIBITION

SESSION EIGHT: PANEL DISCUSSION - REGULATORY PATHS FOR NEW TREATMENT MODALITIES
Chair: Dr Valeria Gigante, Team Lead, One Health Research Priority-setting and Synergy in AMR, WHO

1330
Panellists:
Dr Markus Zeitlinger, University of Vienna, Dr Mimi Yen, Phage Pro, Dr Joe Campbell, National Institute of Allergies and Infectious Diseases (NIAID)

1420
Q&A

1430
Closing remarks
Professor Laura JV Piddock, Scientific Director, GARDP

1435 POSTER VIEWING & EXHIBITION

SPEAKERS

Dr Yewande Alimi

Antimicrobial Resistance (AMR) Program Coordinator, Africa Centres for Disease Control and Prevention & co-lead for the Africa Union Task force on AMR

Dr Yewande Alimi is the Antimicrobial Resistance (AMR) Program Coordinator at Africa Centres for Disease Control and Prevention, and co-lead for the Africa Union Task force on AMR. She co-chairs the Infection Prevention and Control (IPC) Section for COVID-19 response across the continent and provides technical IPC support to the Africa Task Force for Coronavirus.

Dr Alimi is a trained Veterinary Surgeon and holds a Masters degree in Public Health (International Health) from the University of Nottingham in the United Kingdom. Drawing on a range of experience that includes veterinary medicine, public health policy and research, Dr Alimi currently leads the implementation of the Africa CDC Framework for AMR Control in Africa Union member states. She also leads on the One Health activities, development and implementation of one health programs within Africa CDC, across the African Union organizations and member states.

Before joining the Africa CDC, Dr Alimi practised as a Veterinary Surgeon in Nigeria. She worked as a research analyst at the Ludwig Boltzmann Institute of Health Technology Assessment, Austria and CompanDX, United Kingdom.

She serves on several advisory boards and groups across the continent and globally. She is the One Health Technical Advisor for Global Emerging Pathogens Treatment Consortium.

She is a member of the Scientific Task Force to Prevent Pandemics at the Source for the Harvard Global Health Institute (HGHI) and the Harvard T.H. Chan School of Public Health Center.

Dr Richard Alm

Chief Scientist, CARB-X

Richard joined CARB-X following almost 20 years in large pharma Infection R&D teams followed by 4 years at a small antibacterial biotech company. He has supported the progression of small molecule compounds from early discovery through to late-stage clinical development. He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining industry he had two post-doctoral positions in the AMR area, one in Australia and one in Canada. He currently serves as the Chief Scientist at CARB-X.

Dr Greg Basarab

H3D - University of Cape Town

Greg Basarab works as an independent consultant offering >30 years' experience in infectious disease drug discovery and pre-clinical development. He has served as Associate Director on the Executive Committee of the Drug Discovery and Development Centre (H3D) at the University of Cape Town leading DMPK, Biosciences and Medicinal Chemistry groups directed towards eradicating resistant infectious diseases including malaria and TB while helping to drive three compounds to pre-clinical development. Before that, as Associate Director at AstraZeneca, he led multi-disciplinary teams to design novel mode-of-action antibacterials generating three clinical candidates. He is the co-inventor of two AMR drug candidates (zoliflodacin and durlobactam) that are currently in Ph3 clinical trials for treatment of gonorrhea and A. baumannii lung/bloodstream infections, respectively. Greg also worked at DuPont Central Research & Development in antifungals and in automated chemical synthesis. He received a B.S. in Chemistry from the Pennsylvania State University and a Ph.D. in Chemistry from MIT.

Dr Ashima Bhatia

MD – Chief Clinical Officer & Head, Global Clinical Development, Wockhardt

Dr. Ashima Bhatia is a physician with an MD in Clinical Pharmacology from Delhi University.

She has more than 23 years' experience in clinical development, clinical operations and medical affairs in industry and academia.

She has held positions of increasing responsibilities at Eli Lilly, Astra Zeneca, Pfizer and, Johnson & Johnson. She has worked in diverse therapeutic areas like Infectious diseases, cardiovascular, metabolic diseases, respiratory, oncology and critical care. She has worked on new product development strategies and designing and implementation of local and global registration studies from Phase I through IV.She has built and led high performing regional and global teams.

She joined Wockhardt in 2012 and is currently Chief Clinical Officer & Head for Global Clinical development and is responsible for clinical development of NCEs in the anti-infective space. She and her team have successfully filed 6 US INDs, got 2 NDA approvals and are currently running two Phase 3 trials – one in cUTI and the other in CABP. She and her team successfully completed phase I through phase III trials of an IV and an oral anti-MRSA drug, both of which were recently launched in India.

She has over 50 national and international publications to her credit and has presented at numerous conferences and symposia.

Dr Joe Campbell

Program Officer, Division of microbiology and infections diseases (DMID), National Institute of Allergies and Infectious Diseases (NIAID)

I am a program officer in the division of microbiology and infections diseases (DMID) in the National Institute of Allergies and Infectious Diseases (NIAID). My primary role is running the base contract under which our in vitro testing pre-clinical services are conducted (https://www.niaid.nih.gov/research/vitro-assessment-antimicrobial-activity-resources). In addition, I am involved in the running of contracts in our pre-clinical models of diseases base contract (https://www.niaid.nih.gov/research/pre-clinical-models-infectious-disease). Finally, I run DMID's bacteriophage interest group. The goal of this group is to work with the FDA and other federal agencies to promote the clinical use of bacteriophages.

Dr Nagasuma Chandra

PhD Professor Department of Biochemistry Indian Institute of Science, Bangalore, India

Nagasuma Chandra obtained her PhD from the University of Bristol, UK, as a Nehru Centenary British Fellow, in the area of structural biology and did her postdoctoral work at the Molecular Biophysics Unit at the Indian Institute of Science, Bangalore. She is currently a Professor at the Department of Biochemistry at the same institute at Bangalore and additionally affiliated with the Bioengineering and Mathematical biology initiatives. She works in the area of molecular systems biology, Genomic medicine and Bioinformatics has played a key role in the development of these areas in her Institute. Her research is interdisciplinary involving modelling complex biological processes and applying them to study human health and disease. Her research has led to the establishment of an IISc startup dedicated to precision medicine and health systems. She is a Fellow of the Indian Academy of Sciences and the Indian National Science Academy. She serves on the Editorial board of Current Research in Structural Biology.

Dr César de la Fuente

Presidential Assistant Professor, University of Pennsylvania

César de la Fuente is a Presidential Assistant Professor at the University of Pennsylvania, where he leads the Machine Biology Group whose goal is to combine the power of machines and biology to help prevent, detect, and treat infectious diseases. Specifically, he pioneered the development of the first antibiotic designed by a computer with efficacy in animals, designed algorithms for antibiotic discovery, reprogrammed venoms into antimicrobials, created novel resistance-proof antimicrobial materials, and invented rapid low-cost diagnostics for COVID-19 and other infections. De la Fuente is an NIH MIRA investigator and has received recognition and research funding from numerous other groups. Prof. de la Fuente has received over 50 awards. He was recognized by MIT Technology Review as one of the world's top innovators for "digitizing evolution to make better antibiotics". He was selected as the inaugural recipient of the Langer Prize, an ACS Kavli Emerging Leader in Chemistry, and received the AIChE's 35 Under 35 Award and the ACS Infectious Diseases Young Investigator Award. In 2021, he received the Thermo Fisher Award, and the EMBS Academic Early Career Achievement Award "For the pioneering development of novel antibiotics designed using principles from computation, engineering, and biology." Most recently, Prof. de la Fuente was awarded the prestigious Princess of Girona Prize for Scientific Research, the ASM Award for Early Career Applied and Biotechnological Research and was named a Highly Cited Researcher by Clarivate. Prof. de la Fuente has given over 200 invited lectures and his scientific discoveries have yielded over 110 publications, including papers in Nature Biomedical Engineering, Nature Communications, PNAS, ACS Nano, Cell, Nature Chemical Biology, Advanced Materials, and multiple patents.

Professor Sinead Delany-Moretlwe

Director: Research, Wits RHI & Professor of Global Health & Infectious Diseases, University of the Witwatersrand, Johannesburg

Sinead Delany-Moretlwe, MBBCh PhD DTM&H is and Director: Research at Wits RHI Professor of Global Health and Infectious Diseases at the University of the Witwatersrand, Johannesburg. Her research interests span the intersections between sexual and reproductive health (SRH) and infectious diseases, particularly in adolescent girls and young women (AGYW). She has been an investigator on several phase III trials of new HIV prevention technologies and led the landmark trial for cabotegravir as injectable PrEP for women. She has also led several implementation studies to optimize oral PrEP use in adolescent girls and young women (AGYW) in eastern and Southern Africa. She has conducted studies to evaluate HPV screening and vaccination approaches for populations living with HIV, as well as studies of novel treatments and vaccines for gonorrhoea. She is an advisor to the South African National Department of Health PrEP technical working group and serves on several WHO and other advisory committees, including PDVAC, the WHO HIV, Hepatitis and Sexually Transmitted Infectious Scientific and Technical Advisory Committee and co-chairs the WHO HHS pregnancy and breastfeeding therapeutics working group.

Professor Rosemary Dorrington

Professor: Marine natural Products Research, Rhodes University

Rosemary Dorrington (PhD UCT) holds the DST/NRF SARChI Chair in Marine natural Products Research at Rhodes University, Makhanda, South Africa. Prof Dorrington is the South African Principal Investigator of the SA/UK Antimicrobial Drug Discovery Hub funded by the South African Department of Health and the UK Newton Fund through the South African and UK Medical Research Councils. She leads a multidisciplinary team engaged in research across the broad field of marine biodiscovery focusing on the potential of bioactive small molecules as molecular probes for drug development.

Professor Lena Friberg

Professor of Pharmacokinetics and Pharmacodynamics at the Department of Pharmacy, Uppsala University, Sweden

Lena Friberg is Professor of Pharmacokinetics and Pharmacodynamics at the Department of Pharmacy at Uppsala University, Sweden. She obtained her PhD degree in 2003 and spent nearly two years as a postdoc at University of Queensland in Australia. Her research is focused on advancing pharmacometric concepts to support dosing strategies for new and available drugs. She has published >170 articles in the area and has an h-index of 52. Much of her research is focused on antibacterial treatments, e.g. improving quantitative translation of response-time profiles from preclinical (in vitro and in vivo) to patients and pharmacometric approaches to analyze data collected in clinical trials. Lena is Deputy Editor-in-chief of CPT: Pharmacometrics & Systems Pharmacology, and on the boards of PAGE, WCoP and ISAP. She has received the Georgio Segré prize for distinction in the field of PKPD, the Innovation award from ISoP and was in 2021 appointed ISoP fellow.

Dr Valeria Gigante

Team Lead, One Health Research Priority-setting and Synergy in AMR, WHO

Dr. Valeria Gigante is Team Lead at the World Health Organization (WHO) in the AMR Division where she coordinates research and priority-setting.

Dr Gigante worked for the European Medicines Agency, for the Italian Medicines Agency until joining WHO in 2017.

Dr Gigante holds a Master Degree in Pharmacy with training in Microbiology and Hygiene, a Ph.D. in Pharmacology and Toxicology on available therapies for MDR-TB. She has executive education from INSEAD.

Dr Gigante represents WHO in the Scientific Advisory Committees of GARDP, of the AMR Action Fund and in the Advisory Board of the Global AMR R&D HUB as observer.

Dr Peter Jackson

Executive Director, INFEX Therapeutics Ltd

Dr Peter Jackson is an experienced UK-based serial entrepreneur in the life sciences sector. Over the past 15 years, he has created seven new companies, targeting novel therapeutics across infection, oncology and immunology, as well as in agrochemicals and life sciences services. Two of these companies are currently admitted to trading on AIM: Redx Pharma PLC and Bivictrix Therapeutics PLC.

Dr Jackson has over 25 years' experience in the sector, previously holding senior executive roles as commercial director and then Vice President of Avecia's Pharmaceutical Products business unit, following senior commercial and R&D positions at predecessor companies Zeneca and ICI.

Dr Jackson is a member of the Project Advisory Group for NHS England and NICE on the new UK antibiotic reimbursement trial and is a member of a UKRI/BBSRC panel reviewing academic AMR investments and cross-departmental AMR strategy. He is also a special advisor on AMR and pandemic preparedness to the Washington DC-based Milken Institute. Dr Jackson has recently joined the board of the BEAM Alliance, a network of European AMR biotech companies lobbying for the implementation of AMR drug reimbursement reforms in the EU.

Professor Samuel Kariuki

Chief Research Scientist and Director, Research and Development, Kenya Medical Research Institute (KEMRI), Kenya

He has undertaken leadership in the development and implementation of technical guidance on AMR and AMU Nationally and in the region under a One-Health approach. He is a member of the National Antimicrobial Stewardship Committee overseeing the implementation of the National Action Plan in Kenya, and he leads in AMR and infectious disease surveillance for the Africa region in various AMR forums and panels including the Global Foodborne Infections Networks (GFN), Food Safety (FOS), the Fleming Fund, and the WHO STAG-AMR. He has researched and published extensively on the local and global epidemiology of drug-resistant enteric pathogens at the human-animal interface. He is honorary/visiting Faculty at the Wellcome Sanger Institute, Cambridge, the University of Oxford and the Global One-Health Institute, Ohio State University.

Dr Christopher Longshaw

Senior Director, EU Scientific Affairs, Shionogi BV & BSAC Honorary Treasurer

Chris studied Medical Microbiology at Leeds University, UK, gaining his PhD for work on the colonisation factors of coagulase-negative staphylococci. He joined Cubist Pharmaceuticals in 2001, working on a joint EU-project to find novel ways to prevent spread of antimicrobial resistance via inhibition of conjugative plasmid transfer. After a period with Syngenta BioPharma screening for novel medicinal antimicrobials from agrochemical libraries, he swapped R&D for Medical Affairs, joining Wyeth Pharmaceuticals UK (later Pfizer UK) as Scientific Advisor for their Anti-infective portfolio which included piperacillin-tazobactam and tigecycline. Chris joined Astellas Pharmaceuticals Europe in 2010 as Associate Director for Microbiology, working on the development, launch and commercialisation of multiple antimicrobials including telavancin, fidaxomicin, micafungin and isavuconazole and was Country Medical Affairs Manager for Basilea Pharmaceuticals, supporting the commercialisation of isavuconazole and ceftobiprole in the UK.

Chris joined Shionogi Pharmaceuticals in 2017 as EU Scientific Advisor for Infectious Diseases and works with medical, commercial and development teams at National, European and Global levels to provide medical and scientific leadership, most recently focused on the regulatory approval of the antibiotic, cefiderocol.

Chris has co-authored numerous peer-reviewed publications including high impact journals such as Lancet Infectious Disease and Eurosurveillance and was one of the EFPIA co-leads within the Innovative Medicines Initiative/New Drugs 4 Bad Bugs project, DRIVE-AB. Chris is a member of the Scientific Committee for Antibiotic Research UK and has been a member of council for the British Society for Antimicrobial Chemotherapy and Industry representative for the Resistance Surveillance Working Group before taking up the office of Honorary Treasurer from 2018.

Alison Luckey

GARDP

Alison joined GARDP in September 2021 as Medical Lead for the Zoliflodacin program.

As a Pharmaceutical Physician, she brings a wealth and breadth of experience to the team as a result of her 22-year clinical research career, the last 8 years of which have been within late phase drug development in the anti-infectives therapeutic area. As EFPIA Lead (Astra Zeneca and Pfizer) for Innovative Medicine's Initiative's (IMI) COMBACTE CARE consortium, she has most recently been instrumental in developing and maintaining essential public-private collaborations, leveraging unique opportunities and novel ways of working, to successfully deliver the first interventional Phase 2a study of the program and start-up of a Phase 3 program through two corporate transitions and a pandemic.

Prior to this, Alison has worked as a Clinical Research Physician and Principal Investigator in early phase development in both the United Kingdom and New Zealand. Together with colleagues, she established a CRO in New Zealand with a 10-bedded facility specialising in early phase development, including First in Man studies and providing an end-to-end service for small biotech companies as well as large pharma. During this time, she was Deputy Chair of the Upper South Regional Ethics Committee, Ministry of Health, New Zealand.

Alison is a medical graduate (Southampton, UK, 1992) with post graduate clinical experience in Obstetrics & Gynaecology; she holds the Diploma of Pharmaceutical Medicine and is a Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians.

Dr Keith Miller

Senior Lecturer in Medical Microbiology, Sheffield Hallam University

Keith studied Medical Microbiology at the University of Leeds, UK, gaining his PhD for work on antibiotic resistance mechanisms in hypermutable bacteria. He completed post-doctoral projects funded by the UK Department of Health, Novartis and the UK Medical Research Council at the University of Leeds on antibiotic resistance mechanisms of linezolid-resistant staphylococci and the development of novel antimicrobial agents against Mur ligases and RNA polymerase. He then joined Sheffield Hallam University in 2008 where his group research the molecular mechanisms of antibiotic resistance and develop novel natural product derived antimicrobials.

Keith is a former council and grant committee member for the British Society for Antimicrobial Chemotherapy and was also an editorial board member for the Journal of Medical Microbiology, published by the Microbiology Society.

Dr Mirfin Mpundu

Director, ReAct Africa

Public health specialist with over 30 years extensive experience in global health policy, infectious diseases and security, developing innovative sustainable financing options for healthcare delivery and strategic development. As an independent consultant for ICARS and Director for ReAct Africa I provide support on development, implementation, and evaluation of projects in the African region. As part of my portfolio, I have successfully supported several countries with AMR National Action Plan development and implementation and provided technical support to WHO, FAO, OIE, Africa CDC and Southern Africa Development Community (SADC) on AMR strategies and policies. I also Co-chair – External Advisory Board of the Newton AMR Drug Discovery Programme.

Dr Pascale Ondoa

Director of Science & New Initiatives, African Society for Laboratory Medicine (ASLM)

Dr Pascale Ondoa is the Director of Science and New Initiatives of the African Society for Laboratory Medicine (ASLM) since 2016. She is a laboratory scientist focusing on addressing gaps of the laboratory systems and networks in African countries. She leads several Fleming Fund regional grants addressing AMR surveillance data, quality of testing and workforce development across 17 countries in Africa and Asia. Under the of the Mapping AMR and AMU partnership (MAAP), she led the first initiative to systematically collect, process and evaluate large quantities of antimicrobial resistance and antimicrobial consumption data in Africa.

Pascale participated to the development of the AMRSNET framework from the African Centers for Disease Control and Prevention (Africa CDC). She contributes to several laboratory policy and system strengthening activities.

Professor Federico Pea

Full Professor of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Italy

Prof. Dr. Federico Pea, MD, FISAC, is full professor of Pharmacology and Clinical Pharmacology at the Department of Medical and Surgical Sciences at Alma Mater Studiorum – University of Bologna, Italy and Head of Clinical Pharmacology – Dept. for Integrated Infectious Risk Management – IRCCS Azienda Ospedaliero Universitaria di Bologna, Italy. His major research interests are clinical pharmacokinetics and pharmacodynamics of antimicrobials and clinical pharmacological advide programs for optimizing and personalizing therapy by means of real-time therapeutic drug monitoring in special patient populations, such as critically ill patients, hematological patients and elderly patients. He is coauthor (mainly as first or senior author) of more than 240 articles published in international peer reviewed journals (H index = 38; 6434 citations in Scopus). He is Fellow of the International Society of Antimicrobial Chemotherapy, and member of the Executive Committee of the Italian Society of Anti-infective Therapy (SITA). He is Pharmacology Specialty Chief Editor for Frontiers in Antibiotics, Section Editor for PK/PD of the Journal of Global Antimicrobial Resistance and member of the International Editorial Board of Clinical Pharmacokinetics, Antibiotics, Infectious Disease Reports and Pharmaceutics.

Professor Laura JV Piddock

Scientific Director, Global Antibiotic Research & Development Partnership (GARDP)

Laura Piddock joined the Global Antibiotic Research and Development Partnership (GARDP) in January 2018. As GARDP's Scientific Director, Laura leads the Discovery and Exploratory Research and Scientific Affairs programmes, including the REVIVE programme. She also contributes to GARDP's Policy & Advocacy activities.

Laura has been involved in various Policy activities. She was the British Society for Antimicrobial Chemotherapy (BSAC) Chair in Public Engagement, and in this role was the Director of Antibiotic Action and led the secretariat of the UK All Party Parliamentary Group on Antibiotics from 2012 – 2017. Laura was a co-author of the first World Economic Forum report on AMR in 2013, and an expert adviser to the AMR review led by Lord Jim O'Neill.

Dr Manish Shah

VP, Global Clinical Development, Wockhardt

Dr. Manishkumar Shah has more than 24 years' experience in the clinical research industry. He started his career as Clinical Research Associate and then moved to various roles and positions of increased level of responsibilities. He has experience in the areas clinical development of NCEs, Biosimilars and complex ANDAs. He has supported end to end execution of phase I through phase IV clinical trials, Portfolio and project management and CRO oversight. He has worked in both sponsor and CRO sides in various organizations like Pfizer, Quintiles (now IQVIA) and Bristol Myers Squibb. Dr. Shah has done his Masters in Science in Microbiology and has also completed his Ph.D. (Applied Biology) in 1999 from Mumbai University. Currently he is working in Wockhardt in the Global Clinical Development as Vice President.

Dr Ursula Theuretzbacher

Center for Anti-Infective Agents, Vienna

Ursula Theuretzbacher is an expert for antibacterial drug research, discovery/development strategies and policies based on clinical and public health needs. Her broad area of expertise includes public and philanthropic funding strategies for antibacterial drug R&D and initiatives to recover the global pipeline, evaluation and comparative assessment of antibacterial drugs, and optimization of antibacterial therapy concepts. She was member of the coordinating group of the WHO project Priority Pathogen List for R&D and leading scientist for the Clinical Pipeline analysis, and development of Target Product Profiles at WHO.

Professor Gilles P. van Wezel

Director, Institute of Biology & Professor of Microbial Biotechnology, Leiden University, The Netherlands

Gilles van Wezel is Professor of Molecular Biotechnology and Director of the Institute of Biology, Leiden University, The Netherlands. He is also Honorary Fellow at the Royal Academy institute NIOO-KNAW in Wageningen, NL. He studied Chemistry at the Free University in Amsterdam, obtained a PhD in 1994 in Biochemistry in Leiden and worked as a postdoc at the John Innes Centre in Norwich, UK. He was a research fellow for the Royal Netherlands Academy (KNAW) and became full professor in 2010. He received an ERC Advanced grant in 2022 and coordinates several large research consortia, including the EU H2020 network MARBLES on marine microbes and natural products. The overarching aim is to go beyond the known horizons and provide novel insights into the global and specific regulatory pathways in Actinobacteria. In particular, Gilles aims to understand how streptomycetes are able to translate the cacophony of signals they receive in the habitat to then make the right decisions to grow, sporulate and produce secondary metabolites. This information is applied by developing elicitation approaches during antibiotic screening. The research is characterized by strong resonance between fundamental and applied research.

Dr Evelyn Wesangula

Senior AMR Control Specialist, East Central and Southern Africa Health Community (ECSA- HC)

Evelyn Wesangula is a pharmacist with a Msc. Tropical and Infectious Diseases with more than fifteen years of experience at the Ministry of Health in Kenya. She successfully championed the development and implementation of the National Policy and Action Plan for Antimicrobial Resistance from a multi-sectoral perspective in Kenya and the first National Policy and Action Plan on Patient Safety, Health Workers Safety and Quality of Care. Evelyn works with the East Central and Southern Africa Health Community (ECSA- HC) as a senior AMR Control Specialist supporting the implementation of AMR National Action Plans in East Central and Southern Africa with a focus on strengthening AMR surveillance and antimicrobial stewardship. She has worked as a consultant with the World Health Organization developing AMS guidance documents supporting implementation of NAPs. She is a Chatham House Africa Public Health Leaders Fellow, Fleming Fund Policy Fellow and an International Ambassador of the Society of Hospital Epidemiology of America.

Dr Mimi Yen

Founding CEO, Phage Pro

Dr. Minmin Yen (Mimi) researched the use of phages as an intervention for cholera during her thesis work in the Camilli Lab at Tufts University, resulting in publications in Nature Communications and eLife. As a biological engineering undergraduate at MIT, she trained with Professors David Schauer and Darrell Irvine and researched oral vaccine delivery. Passionate about developing innovative solutions for infectious diseases, Mimi was awarded the Howard Hughes Medical Institute MERGE-ID fellowship, which focused on translating bench science to clinical applications, for her graduate education. During her thesis research, Mimi traveled to Haiti to study the cholera epidemic, where she witnessed the need for innovative healthcare solutions. She also served as the U.S. representative in the Young Leaders Circle for three years as a part of American Society of Microbiology's initiative to address the needs of international early-stage scientists. Mimi recently received her Master's in Public Health at Boston University, with a focus in global health and program management.

Dr Markus Zeitlinger

University of Vienna

Markus Zeitlinger studied medicine at the Medical University of Vienna and graduated in 2000. He completed his training as specialist in Internal Medicine and Clinical Pharmacology and advanced to his main current position as Head of the Department of Clinical Pharmacology. In 2007 he received his post-graduate diploma in Clinical Research. Beside clinical trial design his scientific interests cover antimicrobial agents with focus on early phases of clinical research and pharmacokinetics/pharmacodynamics (PK/PD). He has published over 260 peer reviewed publications and book chapters in particular in the areas of antimicrobial agents, vaccines and imaging and is ad hoc reviewer of over 30 journals. As scientific expert to the European Medicines Agency (EMA) he was actively involved in more than 400 scientific advice procedures given by the agency, including 1/3 of all rapid scientific advice procedures during the Covid-19 pandemic. Furthermore he is holds key positions in several national and international scientific societies as well as in a number of national and six European research consortia. International functions include e.g. chairing of the PK/PD working group of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) while national functions include memberships in the Safety Board of the National Vaccine Advisory Committee and the Austrian National Health Board. He is also member of the Senate of the Medical University of Vienna.

POSTERS

Advancing antimicrobial research and development with open access tools and resources: REVIVE
Alexandra Santu, Christiana Onyebujoh, Astrid Pentz-Murr, Laura JV Piddock
GARDP

Comparative Study on the Antibacterial Efficacy of Microbial-mediated Metallic Nanoparticles and their Composite against Multidrug Resistant Chronic Wound Bacterial Isolates
Richard Kolade Omole[1,2], Nkem Torimiro[1], Oluwole Isaac Adeyemi[3], Saravanan Muthupandian[2]
1 Department of Microbiology, Obafemi Awolowo University, Ile-Ife - 220005, Nigeria; 2 AMR and Nanotherapeutics Laboratory, Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai - 600077, India; 3 Department of Pharmacology, Obafemi Awolowo University, Ile-Ife - 220005, Nigeria

Jekyll and Hyde: The evolution of Pseudomonas aeruginosa
Dixita Naik[1], John Wain[1,2], and Benjamin A. Evans[1]
1 Norwich Medical School, University of East Anglia, Norwich, UK; 2 Quadram Institute, Norwich Research Park, Norwich, UK

Identification of Novel Compounds Targeting Bacterial Biofilm Formation: A Combinedin Silico and in Vitro Approach
Maria Galvez-Llompart[1], Riccardo Zanni[1], Jesús Hierrezuelo[2], Diego Romero[2]
1 Department of Physical Chemistry University of Valencia, Spain; 2 Departament of Microbiology, Facultad de Ciencias, Instituto de HortofruticulturaSubtropicalMediterranea La Mayora, IHSM-UMA-CSIC, University of Malaga, Spain;

Actions of spiropyrimidinetriones against Neisseria gonorrhoeae type II topoisomerases
Jessica Collins[1], Gregory Basarab[2], Kelly Chibale[2], Neil Osheroff[1,3]
1 Vanderbilt University, Nashville, TN, USA; 2 University of Cape Town, Rondebosch, South Africa; 3 VATennessee Valley Healthcare System, Nashville, TN, USA

Virtual screening of phytochemicals by targeting multiple proteins of SARS-CoV-2: molecular docking and molecular dynamics simulation studies
Ghulam Mustafa[1]*, Muhammad Azeem[1], Hafiza Salaha Mahrosh[2]
1 Department of Biochemistry, Government College University Faisalabad, Faisalabad-38000, Pakistan; 2 Department of Biochemistry, University of Agriculture Faisalabad, Faisalabad-38040, Pakistan;

Quality of Antimicrobial Discs
Stefan Orszulik
Formerly at De La Rue Currency, Overton UK

The Antibacterial and Plasmid-curing Potential of Bornean Plant Species
M. Valmiki, Dr. P. de Resende, Prof. S. Gibbons, Prof. A. Ganesan
Affiliations: School of Pharmacy, University of East Anglia, Norwich Research Park, NR4 7TJ

Antimicrobial photodisinfection therapy (aPDT) against ESKAPE pathogens
Cristina Romo-Bernal, Jason Hickok, Sheeny Levengood, Roger Andersen, Nicolas Loebel
Ondine Biomedical Inc.

Impact of COVID-19 Pandemic on Antibiotic Utilization in Primary Care: an Interrupted Time Series Analysis

Audrey Huili Lim[1], Norazida Ab Rahman[1], Hazimah binti Hashim[2], Dr Siti Raidah bt Mohamad Azman[3], Mardhiyah binti Kamal[2], Tineshwaran a/l Velvanathan[4], Mary Chok Chiew Fong[4], Sheamini Sivasampu[1]

1 Institute for Clinical Research, National Institutes of Health, Malaysia; 2 Clinical & Technical Pharmacy Branch, Pharmacy Practice & Development Division, Pharmaceutical ServicesProgramme, Ministry of Health; 3 Family Health Development Unit, Public Health Division, Ministry of Health; 4 Pharmacy Research & Development Branch, Pharmacy Policy & Strategic Planning Division, PharmaceuticalServices Programme, Ministry of Health

Out patient antibiotic prescription audit in a public sector hospital in south india – a prospective observational study

Dr. D Suresh Kumar, K Selva Kumar, P Shalini, V Elumalai, G Sanjay, C.P. Yogavigneshwaran, H Shaikh Jassim

A graph theory QSAR-based approach for the identification of potential therapeutic agents against Mycobacterium tuberculosis

Riccardo Zanni, Maria Galvez-Llompart

Department of Physical Chemistry, University of Valencia, Spain

Incidence of Beta Lactamases Mediated Resistance in Gram Negative bacterial uropathogens in Type 2 Diabetic Patients

Ajay Kumar Prajapati[1], VinodKumar C S[2]

1 Laboratory Superintendent, Department of Laboratory Medicine, Central Hospital,South Western Railway, Hubli, Karnataka, India; *2 Professor, SSIMS, Davngere, Karnataka, India*

A Multicentric Cross-Sectional Observational Study on the Antibiotics prescribing patterns in Hospitalized patients in an Indian Tertiary Care Hospitals

Dr. D. Suresh Kumar[1], Ms. S. Safiya Banu[2], Mr. R. Ratheesh[2], Mr. S. Abishek[2]

1 Senior Consultant - Infectious diseases, SIMS Hospital, Vadapalani, Chennai, India; 2 Intern, SIMS Hospital, Vadapalani, Chennai, India

A Prospective observational study on assessing the Antibiotic usage pattern in Discharge patients in a Tertiary Care Hospital

Dr. D. Suresh Kumar[1], Ms. S. Safiya Banu[2], Mr. R. Ratheesh[2], Mr. S. Abishek[2]

1 Senior Consultant - Infectious diseases, SIMS Hospital, Vadapalani, Chennai, India; 2 Intern, SIMS Hospital, Vadapalani, Chennai, India

A Retrospective Observational Study on assessing the use of Antibiotic Prophylaxis for Outpatients in the Dental department in a Tertiary Care Hospital

Dr. D. Suresh Kumar[1], Ms. S. Safiya Banu[2], Mr. R. Ratheesh[2], Mr. S. Abishek[2]

1 Senior Consultant - Infectious diseases, SIMS Hospital, Vadapalani, Chennai, India; 2 Intern, SIMS Hospital, Vadapalani, Chennai, India

The utility of phage therapy in the fight against antibiotic resistant bacteria

Fai yahya, Manar Alhawiti, Asmaa yousuf, Raghad Alqarni, Rehab Ahmed

Pharm D program at the Faculty of Pharmacy, university of Tabuk, Tabuk, Saudi Arabia; Department of natural products and Alternative Medicine, Faculty of Pharmacy, university of Tabuk, Tabuk,Saudi arabia; Department of Pharmaceutics, Faculty of Pharmacy, university of Khartoum, Khartoum, Sudan

Anti-Candidal activity of Micromonospora sp. from Lake Baikal

Collins Chimezie[1], Olesya Melnikova[1], Valeria German[1], Andrey Mukhin[2], Uliana Vasilieva[2], SofiaTsvetikova[1], Maxim Timofeyev[2], Elena Koshel[1]

1 SCAMT, ChemBio Cluster, ITMO University, St. Petersburg, Russia; 2 Institute of Biology, Irkutsk State University, 664003 Irkutsk, Russia

In-silico Study for Phytochemicals with Multi-targeted Activity against Helicobacter Pylori

Ilechukwu A. U., Mmadubugwu H. O., Ejiofor I. I.
Department of Pharmacognosy and traditional medicine, Faculty of Pharmaceutical sciences Nnamdi AzikiweUniversity, Awka, Nigeria

A Retrospective observational study on assessing the use of Pre-operative Surgical Antibiotic Prophylaxis for patients undergoing Neurosurgery in a Tertiary Care Hospital

Dr. D. Suresh Kumar[1], Ms. S. Safiya Banu[2], Mr. R. Ratheesh[2], Mr. S. Abishek[2]
1 Senior Consultant - Infectious diseases, SIMS Hospital, Vadapalani, Chennai, India; 2 Intern, SIMS Hospital, Vadapalani, Chennai, India

Survey of fungal diagnostic stewardship practices in an Indian hospitals

Yogavigneshwaran C.P[1], Dr Suresh Kumar[2]
1 Vels institute of science, technology and advanced studies; 2 ID Consultant, Apollo hospitals, Chennai, Tamilnadu, India

International survey on the implementation of antimicrobial stewardship practices in the hospitals

Aishwarya Balasubramaniam[1], Dr Suresh Kumar[2], Yogavigneshwaran C P[3]
1 Pharm D Intern, VISTAS, Chennai, Tamilnadu, India; 2 ID Consultant, Apollo hospitals, Chennai, Tamilnadu, India; 3 Pharm D Intern, VISTAS, Chennai, Tamilnadu, India

Persimmon by-product extracts interfere with bacterial virulence

Bryan Moreno-Chamba[1,2], Julio Salazar-Bermeo[1,2], María Concepción Martínez-Madrid[1] , Domingo Saura[1], Victoria Lizama[2], Nuria Martí[1,2] , Manuel Valero[1]
1 Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE). EdificioTorregaitán, Universidad Miguel Hernández de Elche (UMH), Avenida de la Universidad s/n, 03202, Elche,Alicante, Spain; 2 Instituto de Ingeniería de Alimentos para el Desarrollo. Universitat Politècnica de València, Avenida FaustoElio s/n, Edificio 8E, Acceso F Planta 0, 46022, Valencia, Spain

Clinical audit of anti-microbial prescribing in a specialist inpatient palliative care unit (IPU)

Dr Sophie Gregg, Dr Maeve Doyle
University Hospital Waterford, Ireland

Level of AMR Awareness and Its Perceived Drivers Among Women of Reproductive Age Attending University and Health Facilities in Southern Nigerian and Northern Uganda

Egwu Kenneth Chukwuebuka[1], Humphrey Beja[2], Akinsehinwa Samuel Ayodeji[3], Govett Anna[4], Emmanuel Benyeogor[5]
1 Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, Nigeria; 2 Department of Midwifery, Faculty of Nursing and Midwifery, Lira University, Lira, Uganda; 3 Department of Microbiology, Faculty of Life Sciences, University of Ilorin, Kwarastate, Nigeria; 4 Cambridge University, United Kingdom; 5 Nigeria Center for Disease Control, Nigeria

Interplay Between Clinical Stringent Response-Activating Mutations, Antibiotic Tolerance and Bacterial Fitness

Joanne K. Hobbs[1,2], Ashley T. Deventer[1], Duncan Bryson[1]
1 Department of Biochemistry and Microbiology, University of Victoria, Canada; 2 Biomedical Sciences Research Complex, School of Biology, University of St Andrews, UK

An epidemiological investigation of the trends and risk factors for antimicrobial resistance in UK sheep Salmonella isolates originating from clinical surveillance

Hannah Jones, Animal and plant health agency (APHA), Dr Martina Velasova (APHA), Dr Lucy Brunton, Royal veterinary college (RVC), Suleiman Muhammad (RVC)

Antibiotic tolerance in Staphylococcus aureus COL: the role of prs

Claire Stevens[1], Ashley Deventer[1], Dr. Joanne Hobbs[1,2], Dr. Alisdair Boraston[1]
1 University of Victoria; 2 University of St Andrews

Stringent Response Activation Promotes Conjugal Transfer in Staphylococcus aureus

Ashley Deventer[1], Claire Stevens[1], Dr. Alisdair Boraston[1], Dr. Joanne Hobbs[1,2]
1 University of Victoria; 2 University of St Andrews

Assessment of availability of essential antimicrobial agents in north India

Dr. Rachna Rohilla[1], Dr. Nusrat Shafiq[2], Tania Sidana[3], Smaila Singh[3], Dr. P.V.M Lakshmi[4]
1 Assistant Professor, Department of Pharmacology, AIIMS Bathinda; 2 Professor, Department of Pharmacology, PGIMER Chandigarh; 3 MSc Pharmacology, PGIMER Chandigarh; 4 Professor, Community and Family Medicine

Proteomic insight into the venomous protein mixtures from selected Hymenopteran insects and their antibacterial activity

Ashish Kumar Lamiyan[1], Kuldeep Giri[2], Srinivas Kiran Ambatipudi[2], Archana Chauhan[3], Neelima R. Kumar[3]
1 Department of Zoology, Panjab Univeristy, Chandigarh-160014; 2 Department of Biosciences and Bioengineering, Indian Institute of Technology, Roorkee,Uttarakhand-247667; 3 Department of Zoology, Panjab Univeristy, Chandigarh-160014

Microbiological activity of MET-X: A Broad-Spectrum Metallo-β-lactamase Inhibitor in Combination with Meropenem

Victoria J. Savage, Nicola Ooi, Derek Lindsay, Andrew Wilkinson and Ian R. Cooper
Infex Therapeutics Ltd

The SA-UK Antimicrobial Drug Discovery Hub: Harnessing the potential of natural products as antimicrobial lead compounds

RL Higgitt[1], M Upton[2], RA Dorrington[1,3]
1 Department of Biochemistry and Microbiology, Rhodes University, Makhanda, South Africa; 2 School of Biomedical Sciences, University of Plymouth, Drake Circus, Plymouth, UK; 3 South African Institute for Aquatic Biodiversity, Makhanda South Africa

Plantimicrobials: Recovering Antimicrobial Producing Bacteria Associated with Flowering Blossoms

Thomas Garry, Stephanie MacLean, Ellie L. Rowlands, Charlotte E. Greenwood, Philip Warburton
University of Plymouth

First report of qepA among E. coli isolated from children under five years being discharged from hospitals in Kenya

Kevin Kariuki[1,3], Mame Mareme Diakhate[2], Susan Musembi[3], Stephanie N. Tornberg-Belanger[4], DoreenRwigi[1], Timothy Mutuma[1], Elizabeth Mutuku[1], Kirkby D. Tickell[2], Olusegun O. Soge[2], Benson O. Singa[1,2], Judd L. Walson[2,4,5], Patricia B. Pavlinac[2,4], Samuel Kariuki[1]
1 Centre for Microbiology Research, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya; 2 Department of Global Health, University of Washington, Seattle, WA, USA; 3 Department of Biochemistry, Biotechnology and Microbiology, Kenyatta University, Kenya; 4 Department ofEpidemiology, University of Washington, Seattle, WA, USA; 5 Department of Pediatrics and Medicine (Allergy and Infectious Diseases), University of Washington, Seattle,WA, USA

Association of meropenem with ethambutol enhances the exposure of Mycobacterium tuberculosis peptidoglycan and promotes its synergistic killing

Francisco Olivença, David Pires, Cátia Silveiro, Elsa Anes, Maria João Catalão
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal

Free online #MedEd resources promoting antifungal stewardship

Elizabeth Bradshaw[1], Angela Brennan[2], Graham Atherton[1], David Denning[2], Riina Richardson[1]
1 National Aspergillosis Centre, Manchester University NHS Foundation Trust; 2 Manchester Fungal Infection Group, University of Manchester

A Collaborative, Equitable, Knowledge Community Approach for Strengthening Global Antimicrobial Resistance Research

Ryan Walker, Delphine Kayem, Godwin Pius Ohemu, Adam Dale, Jeremy Whitty, Elizabeth Allen, Trudie Lang
The Global Health Network, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine University of Oxford, Oxford, UK

Antimicrobial protein chimeras against cancer: Betterment of the diseased

Saumya Surekha
Department of Biochemistry Panjab University, Chandigarh, INDIA-160014

High "Unlikely Results" Reports of Manual Antimicrobial Susceptibility Testing Based on Expected Phenotypes Rules

Yunika Puspa Dewi[1], Intan Pristian Yuliyani[2]
1 Clinical Pathology Division Dr. Sardjito General Hospital; 2 Clinical Pathology Division Dr. Sardjito General Hospital /Faculty of Medicine, Public Health and Nursing,Universitas Gadjah Mada

Prevalence and characteristics of self medication with antibiotics in adults in Tegucigalpa, Honduras

Joyce Nicole Pineda Ordoñez
Graduate of the Catholic University of Honduras - Association for MedicalEducation in Honduras

The role of antimicrobial chemotherapy in the clinical management of acute suppurative thyroiditis

Nicolò Soldovieri[1], Roberto Parisi[2]
1 Undergraduate Student, Department of Biological Sciences, Università degli Studi di Salerno, 84084,Salerno (SA);
2 Undergraduate Student, Department of Medicine, Surgery and Dentistry, Università degli Studi di Salerno,84084, Salerno (SA)

Material dependant antibiofilm activity of coliphages

Pallavi Bhat, Shreya Bhat, Nupur Lilaramani, Apoorva R Kenjar, Juliet Roshini Mohan Raj
Nitte (Deemed to be University), Nitte University Centre for Science Education and Research,Deralakatte, Mangaluru

Infection control of Healthcare-associated infections in Ukraine

Y. Konechnyi, O. Korniychuk
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Molecular characteristics of Staphylococcus aureus and association risk factors to infection among hospitalized patients in a tertiary care hospital in Enugu, Nigeria

Onwubu CP[1], Nwafia IN[1,2], Ozumba UC[1,2]
1 Department of Microbiology, University of Nigeria Teaching Hospital Ituku-Ozalla, Enugu State Nigeria; 2 Department of Microbiology, Faculty of Medical Sciences, College of Medicine, University of Nigerialtuku/Ozalla Campus, Enugu

Biological investigation of copper mixed ligand coordination compounds with 3,5-dibromosalicylaldehyde 4-allylthiosemicarbazone and N-heteroaromatic bases in the search of new antimicrobial agents

Ianina Ulchina[1], Vasilii Graur[1], Greta Balan[2], Victor Tsapkov[1], Aurelian Gulea[1]
1 Moldova State University; 2 State University of Medicine and Pharmacy "Nicolae Testemițanu"